Hookipa Pharma Inc (NASDAQ:HOOK) Expected to Post Q1 2024 Earnings of ($0.18) Per Share

Hookipa Pharma Inc (NASDAQ:HOOK) – Research analysts at HC Wainwright upped their Q1 2024 EPS estimates for shares of Hookipa Pharma in a report released on Monday, March 25th. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($0.18) for the quarter, up from their previous estimate of ($0.22). HC Wainwright currently has a “Buy” rating and a $6.50 target price on the stock. The consensus estimate for Hookipa Pharma’s current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Hookipa Pharma’s Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.19) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.60) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.67) EPS and FY2027 earnings at ($0.22) EPS.

Separately, Royal Bank of Canada reiterated an “outperform” rating and set a $5.00 target price on shares of Hookipa Pharma in a research report on Monday.

Hookipa Pharma Price Performance

Shares of NASDAQ HOOK opened at $0.71 on Wednesday. Hookipa Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $2.05. The firm has a market capitalization of $59.77 million, a P/E ratio of -0.81 and a beta of 1.03. The company’s 50 day simple moving average is $0.70 and its 200 day simple moving average is $0.63.

Institutional Trading of Hookipa Pharma

A number of hedge funds have recently modified their holdings of HOOK. Knoll Capital Management LLC increased its stake in Hookipa Pharma by 1,739.1% in the second quarter. Knoll Capital Management LLC now owns 5,517,385 shares of the company’s stock valued at $4,855,000 after purchasing an additional 5,217,385 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of Hookipa Pharma in the 2nd quarter valued at $1,008,000. Jefferies Financial Group Inc. acquired a new position in shares of Hookipa Pharma in the 4th quarter valued at $849,000. Renaissance Technologies LLC increased its position in shares of Hookipa Pharma by 7,610.5% in the 2nd quarter. Renaissance Technologies LLC now owns 909,836 shares of the company’s stock valued at $801,000 after buying an additional 898,036 shares in the last quarter. Finally, CHI Advisors LLC acquired a new stake in Hookipa Pharma during the 2nd quarter worth $694,000. 63.88% of the stock is currently owned by institutional investors and hedge funds.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.